Differentiating Molecular Risk Assessments for Prostate Cancer

Reviews in Urology

Michael Schulster¹  Marc A. Bjurlin²  Benjamin Press³ 

[1] Department of Urology, NYU Langone Health, New York, NY;Department of Urology, NYU Langone HospitalBrooklyn, Brooklyn, NY;School of Medicine, Rutgers New Jersey Medical School, Newark, NJ

关键词: Biomarkers;    Prostate cancer;    Prostate-specific antigen;    PSA;    Screening;   

DOI  :  10.3909/riu0787

学科分类：基础医学

来源: MedReviews, LLC

【 摘 要 】

It is critically important to the evolving goals of prostate biopsy to find clinically significant cancer with lethal potential and avoid detection of indolent disease. Better tests and markers are required for improved detection of clinically significant prostate cancer and avoidance of biopsies in men with indolent disease. Currently, there are myriad alternative prostate cancer risk-assessment tests available derived from serum and urine that are designed to improve the specificity for detection of “significant” prostate cancer. Herein we discuss these tests and their clinical implications.

【 授权许可】

Unknown